---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-277328"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T07:15:16.607710+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011

## Summary
- NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.
- Sarcoma: Go criteria met for UPS, osteosarcoma, liposarcoma, and synovial sarcoma into Part 2.
- UPS (Phase 1&2, n=10): ORR 50% (4/8 evaluable), 3-month PFS rate 50%, median PFS 6.8 months.
- Osteosarcoma (n=6): 3-month PFS rate 66.7%; liposarcoma (n=6): 66.7%; synovial sarcoma (n=5): 54%.
- FDA supportive of proposed registrational Part 2 study in UPS (n=80, primary endpoint ORR); enrollment expected by year-end 2022.

## SEC filing metadata
- accession: 0001193125-22-277328
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/0001193125-22-277328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/d416713d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-277328
- JSON: https://secwatch.observer/filing/0001193125-22-277328.json
- Plain text: https://secwatch.observer/filing/0001193125-22-277328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.